Image: MedCity NewsMerck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs - MedCity News
• Merck has received FDA approval for Lipfendra, the first oral pill in the PCSK9 inhibitor class of cholesterol-lowering medications. • Unlike traditional PCSK9 inhibitors that require injections, Lipfendra is a macrocyclic peptide specifically designed for oral administration. • This development provides a more convenient alternative for patients who require stronger cholesterol management than standard statins can offer.
medcitynews.com




